We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Afa5.0
Afamelanotide Research
Mostly mechanism / observational
17 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Afamelanotide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2010–2026 with a typical study size of 200 participants.
Based on 17 studies · 3 RCTs · 568 total participants
Confidence
Moderate confidence
By outcome
Photoprotection & EPP
Mostly mechanism / observational14 studies
Safety & melanocytic risk
Mostly mechanism / observational6 studies
Skin pigmentation & vitiligo
Mostly mechanism / observational5 studies
Active research area
8 studies in the last 5 years
201020182026
1Systematic Review2023
Heerfordt IM, Lerche CM, Philipsen PA, Wulf HC · Biomed Pharmacother (2023)
In plain English: Moreover, to ensure benefit for patients and access to therapy after regulatory approval, it also would be important to generate data on the relative safety and efficacy as compared to afamelanotide.
Barman-Aksözen J, Granata F, Wäscher S, Falchetto R, Dechant C. · Expert opinion on pharmacotherapy (2026)
Areas covered This narrative review (using Pubmed and trial databases) aims to provide an overview of the status of development of dersimelagon and bitopertin, with a focus on the prevention of phototoxicity.
Expert opinion The currently available trial data on dersimelagon and bitopertin suggests treatment effects in EPP as compared to placebo control groups.
However, safety and efficacy of dersimelagon and bitopertin need to be further characterized.
In plain English: These advances must now be widely communicated and translated into equitable access for children across Europe.
Toenne M, Schaefer T. · European journal of pediatrics (2025)
Despite characteristic features, diagnosis is often delayed due to low awareness in paediatric care.
What is New: • This mini-review proposes a practical diagnostic algorithm for paediatric primary care and highlights key clinical clues to sensitise general paediatricians to EPP.
It also reviews emerging treatment options such as afamelanotide, already approved for adults, with promising adolescent data.
In plain English: Regulatory frameworks and dermatologic guidance must evolve to reflect the expanding landscape of sunless tanning modalities.
Resnick G, Khajeh-Afzaly M, Yousefian F, Raza A, Issa NT. · The Journal of clinical and aesthetic dermatology (2026)
Conclusion Sunless tanning agents offer UV-free alternatives for cosmetic pigmentation but are not without risk.
While DHA and melanotan remain the dominant agents in current use, forskolin and carotenoids offer alternative pathways for pigmentation and photoprotection.
Further clinical studies are necessary to evaluate long-term safety, efficacy across skin types, and formulation optimization.
8Observationaln=230 · medium study2024
In plain English: We suggest that future guidelines include continuous monitoring of vitamin D and a prescription for cholecalciferol in all patients with EPP, including those treated with afamelanotide.
Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, Kuerten V, Schelonke K, Homey B, Langendonk JG. · The British journal of dermatology (2024)
Previous studies have shown that 47-63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis.
The prevalence of vitamin D deficiency and severe deficiency remained high despite afamelanotide treatment (< 50 nmol L-1 in 71.8% of patients and < 30 nmol L-1 in 48.1%, respectively).
Afamelanotide treatment alone did not lead to a significant average increase in vitamin D levels [β = 0.5, 95% confidence interval (CI) -3.2 to 4.2].
In plain English: The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.
Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P. · Photodermatology, photoimmunology & photomedicine (2025)
EPP patients reported a significant increase in QoL compared with baseline values (p < 0.0001) and 91.0% of patients who started treatment continue being treated.
The safety profile of afamelanotide in patients over 70 years of age is consistent with the overall patient population.
Conclusions Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients.
In plain English: In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP... enabled patients to spend more time in direct sunlight without pain.
Kim ES, Garnock-Jones KP. · Am J Clin Dermatol (2016)
Drug review summarizing the approved 16 mg controlled-release subcutaneous implant for EPP
Confirmatory Phase 3 trial CUV039 increased pain-free sun-exposure time and time to first phototoxicity symptoms vs placebo
Generally well tolerated; no drug-related serious adverse events; common reactions headache and implant-site reactions
In plain English: Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. · Clin Pharmacokinet (2017)
Pharmacokinetic/pharmacodynamic review of the first α-MSH analogue and MC1R agonist
Subcutaneous route had full bioavailability; oral and transdermal produced no measurable levels or pigmentation
Controlled-release implant is effective at lower dose than daily injections; approved by EMA in 2014 for EPP phototoxicity
In plain English: The trial results were significant, although the effects were not very large in absolute terms, and the risk-safety profile is favorable today.
Minder EI, Schneider-Yin X. · Expert Rev Clin Pharmacol (2015)
Review of the rationale and Phase II/III results of afamelanotide (CUV1647) in protoporphyria
Trial results were statistically significant though absolute effects were modest
High compliance and consistent effectiveness across six years of compassionate-use in Switzerland
In plain English: Increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi.
Habbema L, Halk AB, Neumann M, Bergman W. · Int J Dermatol (2017)
Review of risks of unregulated α-MSH analogues (melanotan I and II) used for tanning
Contrasts these with afamelanotide, the only α-MSH analogue approved for limited medical indications and 'thoroughly tested and deemed safe'
Case reports link unregulated melanotan to melanocytic changes in moles and new dysplastic nevi; four reports describe melanomas emerging from existing moles
In plain English: There is randomized controlled trial (RCT) evidence for the successful use of afamelanotide in several conditions beyond erythropoietic protoporphyria, including polymorphic light eruption and vitiligo.
Wu J, Cotliar R. · J Drugs Dermatol (2021)
Review of afamelanotide (Scenesse), FDA-approved to increase pain-free sunlight exposure in adults with EPP
Dual photoprotective and anti-inflammatory effects underpin interest in other photosensitive diseases
RCT evidence in polymorphic light eruption and vitiligo; smaller studies in acne, Hailey-Hailey disease and solar urticaria
In plain English: Although early, results of the first trials of afamelanotide for PP are promising and the risk-safety profile appears favorable today.
Minder EI. · Expert Opin Investig Drugs (2010)
Early review of afamelanotide, a first-in-class α-MSH agonistic analogue, in protoporphyria
Describes MC1R-mediated signaling and the rationale for photoprotection in a disease of absolute sunlight intolerance
Summarizes the first protoporphyria trials and adverse-effect/safety issues